RAIN - Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress
NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an abstract accepted as a proffered paper presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland.
| Presentation Title: |
| MDM2 inhibitor milademetan: safety profile and management of adverse events (AEs) |
| Presentation Number: |
| 43O |
| Presenter: |
| Chiara Fabbroni, MD, National Cancer Institute, Milan, Italy |
| Session Date and Time: |
| Tuesday, March 21, 2023, 10:50am-12:10pm Central European Time |
| Location: |
| Hall A |
A copy of the presentation materials can be accessed by visiting the “ Resources ” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.
About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of the MDM2-p53 complex that reactivates p53.
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com